Investigating how kidney function and weight affect blood pressure changes in people living with HIV using INSTIs.
Assessing the mediating role of kidney function and weight/BMI in the association between INSTI use and blood pressure changes and hypertension in PWH: a secondary analysis of the REPRIEVE study.
This study is looking at how certain HIV medications called integrase strand transfer inhibitors (INSTIs) might affect heart health, particularly blood pressure, in people living with HIV, and it aims to help doctors understand these effects better.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11079356 on NIH RePORTER |
What this research studies
This research examines the cardiovascular risks associated with integrase strand transfer inhibitors (INSTIs) in individuals living with HIV, specifically focusing on blood pressure and hypertension. By analyzing data from the REPRIEVE study, the project employs advanced statistical techniques to assess the causal effects of INSTI use on blood pressure. It also explores how kidney function and body mass index (BMI) mediate these effects, providing insights into the physiological pathways involved. This comprehensive approach aims to enhance understanding of the cardiovascular implications of INSTIs in clinical practice.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently using integrase strand transfer inhibitors.
Not a fit: Patients not using INSTIs or those without hypertension may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved management of blood pressure and cardiovascular health in people living with HIV who are using INSTIs.
How similar studies have performed: Previous research has shown promising results in understanding cardiovascular risks associated with antiretroviral therapies, making this approach both relevant and potentially impactful.
Where this research is happening
Boston, United States
- Boston University Medical Campus — Boston, United States (Active)
Researchers
- Principal investigator: Brennan, Alana Teresa — Boston University Medical Campus
- Study coordinator: Brennan, Alana Teresa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.